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Abstract
Background
Core outcome sets (COS) can enhance the relevance of research by ensuring that out-
comes of importance to health service users and other people making choices about health
care in a particular topic area are measured routinely. Over 200 COS to date have been
developed, but the clarity of these reports is suboptimal. COS studies will not achieve their
goal if reports of COS are not complete and transparent.
Methods and Findings
In recognition of these issues, an international group that included experienced COS devel-
opers, methodologists, journal editors, potential users of COS (clinical trialists, systematic
reviewers, and clinical guideline developers), and patient representatives developed the
Core Outcome Set–STAndards for Reporting (COS-STAR) Statement as a reporting guide-
line for COS studies. The developmental process consisted of an initial reporting item gen-
eration stage and a two-round Delphi survey involving nearly 200 participants representing
key stakeholder groups, followed by a consensus meeting. The COS-STAR Statement
consists of a checklist of 18 items considered essential for transparent and complete report-
ing in all COS studies. The checklist items focus on the introduction, methods, results, and
discussion section of a manuscript describing the development of a particular COS. A limi-
tation of the COS-STAR Statement is that it was developed without representative views of
low- and middle-income countries. COS have equal relevance to studies conducted in
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these areas, and, subsequently, this guideline may need to evolve over time to encompass
any additional challenges from developing COS in these areas.
Conclusions
With many ongoing COS studies underway, the COS-STAR Statement should be a helpful
resource to improve the reporting of COS studies for the benefit of all COS users.
Introduction
There is growing recognition that insufficient attention has been paid to the outcomes mea-
sured in clinical trials, which need to be relevant to health service users and other people mak-
ing choices about health care if the findings of research are to influence practice and future
research. In addition, outcome reporting bias, whereby results are selected for inclusion in a
trial report on the basis of those results, has been identified as a problem for the interpretation
of published data.
The development and implementation of core outcome sets (COS) is drawing increasing
attention across all areas of research in health [1] and has relevance for research practice on a
global scale. A recent survey reveals that some trialists, systematic reviewers, and guideline
developers (COS users) do now refer to COS studies as a starting point for outcome selection
in their work [1]. The use of COS can help improve the consistency in outcome measurement
and reduce outcome reporting bias, which has led to much unnecessarywaste in the produc-
tion and reporting of research [2].
A recently updated systematic review identified over 200 published COS studies [1], and
many more are known to be under development [3]. The first step in COS development is typi-
cally “what to measure,” whereas the “how” and “when” usually come later. The value of a COS
depends largely on why and how it was developed. The credibility of the group that has devel-
oped the COS, in relation to their experience of outcome assessment and how they have
engaged with key stakeholders during the development process, may influence subsequent
uptake of the COS. Furthermore, the reporting quality of COS development studies is also rele-
vant to implementation. Recent work shows that reporting quality is currently variable [4],
restricting the ability of potential users of COS, for example clinical trialists, systematic review-
ers, and guideline developers, to assess the relevance to their own work.
A COS has previously been defined as an agreed standardised set of outcomes that should
be measured and reported, as a minimum, in all clinical trials in specific areas of health or
health care [2]. COS are being developed for settings other than clinical trials. Although previ-
ous recommendations have beenmade regarding the reporting of a Delphi survey component
of a COS study [5], it is timely to gain wider consensus given the increasing activity in this area,
particularly because various other methods and components are incorporated in the COS
development process [1]. In this article, we present the results of a research project, in which
the objective was to develop a guideline (Core Outcome Set–STAndards for Reporting [COS-
STAR]) for the reporting of studies developing COS using an approach proposed by the
Enhancing the QUAlity and Transparency Of health Research (EQUATOR) Network [6]. The
reporting checklist is relevant regardless of the consensus methodologyused in the develop-
ment of the COS and can be applied to COS developed for effectiveness trials, systematic
reviews, or routine care [7].
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Terminology
A COS describeswhat should bemeasured in a particular research or practice setting, with sub-
sequent work needed to determine how each outcome should be defined or measured. A previ-
ous review found that only 38% of published studies contained recommendations about how
to measure the outcomes in the COS [4]. This reporting guideline was developed to address
this first stage of development, namely, what should be measured.
Ethical Approval
The University of Liverpool Ethics Committee was consulted and granted ethical approval for
this study (Reference RETH000841). Informed consent was assumed if a participant responded
to the Delphi survey or agreed to attend the consensus meeting.
Development of the COS-STAR Statement
A full protocol outlining the Delphi procedures for the COS-STAR study was published else-
where [8], including the intention to produce an associated Explanation and Elaboration (E+E)
document in which the meaning and rationale for each checklist item is given.
A preliminary list of 48 reporting items was developed from a previous systematic review of
COS studies involving a Delphi survey [5], the personal experiences of COS development, and
reporting by the project management group (The COS-STAR Group). This preliminary list of
potential reporting items was included in an international two-round Delphi survey in order to
ascertain the importance of these reporting items.
The Delphi survey involved four key stakeholder groups, chosen to encompass aspects of
COS development, reporting, and uptake. Invitations by email were sent to the following: (i)
lead authors of 196 published COS studies in the Core OutcomeMeasures in Effectiveness Tri-
als (COMET) database, with a request to also forward on the invitation to any methodologist
involved; (ii) editors of 250 journals in which COS studies have been published and 70 journals
involved with CoReOutcomes inWomeN’s health ([CROWN], http://www.crown-initiative.
org/), an initiative endorsing the uptake of COS; (iii) potential users of COS who were (a) prin-
cipal investigators of open phase III/IV trials, commercial or non-commercial, registered on
clinicaltrials.gov (20% random sample from 8,449 registered trials) or (b) 76 Coordinating Edi-
tors from 53 Cochrane ReviewGroups; and (iv) 33 patient representatives from previous
COMET workshops and the COMET Public and Patient Participation, Involvement and
Engagement (PoPPIE) Working Group. It did not prove possible to invite clinical guideline
developers listed on the Guidelines International Network website (http://www.gin2015.net/
about/) due to this being a member organisation, so a question about involvement in clinical
guideline development was added to the survey instead. The aim was to recruit as many indi-
viduals from each stakeholder group as possible for the Delphi exercise. Participants were sent
a personalised email outlining the project as described in the study protocol together with a
copy of the first systematic review of COS studies [4].
Delphi participants rated the importance of each reporting item on a scale from 1 (not impor-
tant) to 9 (critically important) as defined in the protocol [8]. In round one of the Delphi study,
participants could suggest new reporting items to be included in the second round. In round
two, each participant who participated in round one was shown the number of respondents and
distribution of scores for each item for all stakeholder groups separately, together with their own
score from round one. An additional nine reporting items were suggested in round one of the
Delphi exercise and were scored in round two. Consensus, defined a priori [8], was achieved if at
least 70% of the voting participants from each stakeholder group scored between 7 and 9. COS
developers (n = 25), COS users (n = 107), medical journal editors (n = 40), and patient
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representatives (n = 11) participated in both rounds, with 13 individuals also having been
involved in clinical guideline development. The variable number of respondents per stakeholder
group did not affect the results, because feedback in round two was presented by group. The
Delphi process was conducted and managed using DelphiManager software developed by the
COMET Initiative (http://www.comet-initiative.org/delphimanager/). The anonymised data
from both rounds of the Delphi process, itemised by stakeholder group, are available in S1 Del-
phi Data.
The consensus meeting was a one-day event held in London, United Kingdom, in January
2016, with 17 international participants, including COS developers (n = 6), medical journal
editors (n = 4), COS users (n = 5) [trialists (n = 1), Cochrane systematic review co-editors
(n = 2), and clinical guideline developers (n = 2)], and patient representatives (n = 2). Individu-
als were selected to be invited to the meeting using the following broad principles: (i) Delphi
participants who completed both rounds; (ii) a balance across the four stakeholder groups; (iii)
a balance amongst COS developers of those using Delphi surveys and those using other meth-
ods; (iv) a balance across COS users of trialists, systematic reviewers, and guideline developers;
and (v) a reasonable geographic spread. Initial invitations were determined by the authors
based on their knowledge of individuals’ expertise. If an individual could not attend, they were
replaced by someone else from the same stakeholder group wherever possible.
The roles of each participant were not mutually exclusive, and there was a mix of clinical
and methodological experience. The objective of the meeting was to discuss and vote on the
series of 57 reporting items thought to be potentially important for inclusion in the COS-STAR
checklist. Three additional participants (one facilitator and two note takers) attended the meet-
ing but did not participate in the discussion or voting.
The Delphi results for all 57 reporting items were presented to the consensus meeting par-
ticipants prior to and during the meeting (S1 ConsensusMatrix Delphi). A copy of the consen-
sus meeting slides showing the response rates, geographical distribution, and Delphi round two
results for each stakeholder group can be found in S1 ConsensusMeeting Presentation.
Although the response rate to the surveywas low, over 86% (183/214) of round one partici-
pants completed round two, with no evidence of attrition bias between rounds (S1 Consensus
Meeting Presentation).
Members of the COS-STAR group (study authors) who could not attend the meeting were
contacted in advance to discuss the results; their comments were documented and fed into the
meeting discussion. Following presentation of the Delphi result for each potential reporting
item, the item was discussed and then voted on by the meeting participants, and retained if
more than 70% of the voting participants (at least 12 of the 17 voting participants) scored
between 7 and 9. Voting was undertaken using OMBEA response (http://www.ombea.com/).
During discussion of the second Consensus Process item, “Description of what information
was presented to participants about the consensus process at its start,” one participant com-
mented on the absence of an item related to ethical approval. The group agreed to vote on this,
and consensus was achieved that this item should be included in the reporting guideline (S1
ConsensusMeeting Critical Scores). This issue has becomemore relevant as the inclusion of
patients as participants in COS development has increased.
Discussion of the format of the reporting checklist was given consideration by the manage-
ment group. It was confirmed that the required items would be relevant to the reporting of a
COS regardless of whether it had been developed for effectiveness trials, systematic reviews, or
routine care. A word of warning was given by those participants at the meeting with previous
experience of reporting guideline development: avoid making the first guideline too stringent
and risk developers not using it. The need to merge some reporting items and create some sub-
items was noted, together with suggestions for an explanatory document to enhance the
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usefulness of the final COS-STAR checklist. Specifically, the following amendments were made
by the COS-STAR group after the meeting:
(1) Participants (methods): The four items under this topic were considered to overlap. The
suggestion was made, and accepted by the group, that one item covering the sub-items of
who, how, and why would be more meaningful.
(2) Consensus process: There was general agreement that although all five items under this
topic could provide useful information, some were too specific to be included, acknowledg-
ing that there is no gold standard approach. The suggestion was made, and accepted by the
group, that one item covering the description of the consensus process would more likely be
followed.
(3) Outcome scoring: a suggestion was made to include both aspects in a single item.
(4) Participants (results): a suggestion was made to combine these issues into a single item.
(5) Outcome results: there was general agreement that these multiple items were too detailed
and should be merged together, elaborating on the issues in the E+E document (S1 Explana-
tion and Elaboration).
(6) Limitations: it was agreed that it was good practice to include an item related to limitations
and include the examples provided in the E+E document.
Following the meeting, a draft of the COS-STAR checklist was circulated to the COS-STAR
group and the remainder of the consensus meeting attendees. All comments and revisions
were taken into consideration and the checklist revised accordingly. The process of obtaining
feedback and refining the checklist was repeated until no further changes were needed.
The comprehension of the final checklist items was reviewed by two expert guideline devel-
opers (DGA,DM). Testing was undertaken by two COS developers who were writing up their
COS studies. Two researchers currently developing COS also reviewed the statement. Testers
were independent of the COS-STAR development process. Feedback from this exercise
informed the final version of the COS-STAR checklist.
The COS-STAR Statement
The 18-item COS-STAR checklist presented in Table 1 applies to COS development studies for
which the aim is to decidewhich outcomes should be included in the COS and does not extend
to cover the reporting of work to determine how those outcomes should be defined or measured.
The checklist aims to cover the minimum reporting requirements related to the background,
scope,methods, results, conclusion, and limitations of such studies. In the accompanying E+E
document (S1 Explanation and Elaboration), explanations are provided for the meaning and
rationale for each checklist item. The checklist is designed to be applicable regardless of consensus
methodologyused to develop the COS (inclusive of mixedmethods) and the various participant
groups whomay have been involved in selecting outcomes (inclusive of patient representatives),
as identified in a previous systematic review [4]. The COS-STAR checklist provides guidance for
minimal COS study reporting, but, in certain circumstances, additional reporting items may be
warranted at the discretion of the study authors. For example, study authors may wish to describe
the steps in deciding how to measure the core outcomes if this was considered [9].
Discussion
The COS-STAR checklist was developed using an approach that has been recommended for
developingmedical reporting guidelines [6]. The intention of the COS-STAR checklist is to
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promote the transparency and completeness of reporting of COS studies such that COS users
can judge whether the recommended set is relevant to their work. For example, although the
adequacy of the description of the scope of a COS is increasing [1], further improvement is
needed in order for uptake to be maximised and, in turn, assessed.
Table 1. Core Outcome Set-STandards for Reporting: The COS-STAR Statement.
SECTION/TOPIC ITEM
No.
CHECKLIST ITEM
TITLE/ABSTRACT
Title 1a Identify in the title that the paper reports the development of a COS
Abstract 1b Provide a structured summary
INTRODUCTION
Background and
Objectives
2a Describe the background and explain the rationale for developing the
COS.
2b Describe the specific objectives with reference to developing a COS.
Scope 3a Describe the health condition(s) and population(s) covered by the COS.
3b Describe the intervention(s) covered by the COS.
3c Describe the setting(s) in which the COS is to be applied.
METHODS
Protocol/Registry Entry 4 Indicate where the COS development protocol can be accessed, if
available, and/or the study registration details.
Participants 5 Describe the rationale for stakeholder groups involved in the COS
development process, eligibility criteria for participants from each
group, and a description of how the individuals involved were identified.
Information Sources 6a Describe the information sources used to identify an initial list of
outcomes.
6b Describe how outcomes were dropped/combined, with reasons (if
applicable).
Consensus Process 7 Describe how the consensus process was undertaken.
Outcome Scoring 8 Describe how outcomes were scored and how scores were
summarised.
Consensus Definition 9a Describe the consensus definition.
9b Describe the procedure for determining how outcomes were included or
excluded from consideration during the consensus process.
Ethics and Consent 10 Provide a statement regarding the ethics and consent issues for the
study.
RESULTS
Protocol Deviations 11 Describe any changes from the protocol (if applicable), with reasons,
and describe what impact these changes have on the results.
Participants 12 Present data on the number and relevant characteristics of the people
involved at all stages of COS development.
Outcomes 13a List all outcomes considered at the start of the consensus process.
13b Describe any new outcomes introduced and any outcomes dropped,
with reasons, during the consensus process.
COS 14 List the outcomes in the final COS.
DISCUSSION
Limitations 15 Discuss any limitations in the COS development process.
Conclusions 16 Provide an interpretation of the final COS in the context of other
evidence, and implications for future research.
OTHER
INFORMATION
Funding 17 Describe sources of funding/role of funders.
Conflicts of Interest 18 Describe any conflicts of interest within the study team and how these
were managed.
doi:10.1371/journal.pmed.1002148.t001
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The COS-STAR E+E document (S1 Explanation and Elaboration) was developed to provide
an explanation of each of the COS-STAR checklist items and to provide a framework for good
reporting practices, with examples, for those interested in conducting and reporting COS
development work. It follows a similar format to that used in other explanatory documents
[10,11]. The E+E document also describes the endorsement and implementation strategies
planned for the COS-STAR Statement.
COS-STAR is not a quality assessment tool and should not be used in this way, for example,
to compare the validity of similar related COS. Similarly, the checklist does not make recom-
mendations about which methodology should be used or which stakeholder groups to include
to reach consensus in COS development projects; guidance on such issues can be found else-
where [2,12]. As an example, several studies have looked at developing COS in childhood
asthma, each using different methodology and proposing slight variations in the core outcomes
[13–16]. The COS-STAR Statement would not distinguish which of these COS should be used,
although it may be useful for critical appraisal of published COS.
As with similar reporting guidelines [17] that have undergone several revisions, COS-STAR
is an evolving guideline and may well require modification in the future. The consensus meet-
ing participants acknowledged that there is limited empirical evidence and methodological
development relating to some of the reporting items that were considered for inclusion and
chose to exclude those items until these issues are better understood. As an example, there is
some evidence that the method of feedback does influence how people score outcomes [18],
which perhaps suggests that this is important information to report. However, until there is
better guidance on how COS developers should present feedback, the item was excluded from
the current reporting checklist.
The guidelinemay also require modification as new stakeholder groups with relevant
interests and experience emerge. For example, regulators have recently recommended the
use of COS in trials of medicinal products in patients with asthma [19] and will be encour-
aged to provide feedback on the statement. The geographical spread of participants in the
Delphi survey, and consequently the consensus meeting, is representative of COS study
developers, being predominantly North American and European [4]. This is recognised as a
limitation, however, of both COS study development and this reporting guideline, given the
equal relevance to low- and middle-income countries. Patient representatives, rather than
patients, were invited to participate. Due to this being a relatively complex area of methodol-
ogy, individuals known to have had some level of involvement with COS development were
selected, thereby increasing their understanding. As patient involvement and participation
in COS development increases, their contribution to a future revision of this reporting guide-
line will be sought. An important objective of the COMET Initiative is to promote wider
involvement.
Although the acceptance rate to the Delphi invitation may appear low, participation in
round two was above 85% in each stakeholder group, with no evidence of attrition bias (S1
ConsensusMeeting Presentation). Readers are invited to submit comments, criticisms, experi-
ences, and recommendations via the COMET website (http://www.comet-initiative.org/
contactus), which will be considered for future refinement of the COS-STAR Statement.
Supporting Information
S1 ConsensusMatrix Delphi. Consensusmatrix for round one and round two of the COS-
STAR Delphi survey.
(DOCX)
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S1 ConsensusMeeting Critical Scores. Percentages of participants scoring each item as crit-
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consensusmeeting.
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S1 Delphi Data. Delphi Data for round one and round two of the COS-STAR Delphi sur-
vey.
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